Novel oncology platform targeting solid tumors with precision virotherapy. Building toward clinical validation. NYSEAMERICAN: $CLDI
San Diego, California
Joined June 2022
- Tweets109
- Following59
- Followers223
- Likes72
#ICYMI: $CLDI's CEO Eric Poma, Ph.D. spoke with BioPharma Boardroom about the #RedTail platform, CLD-401 and Calidi’s approach to reaching primary and metastatic tumors.
🔗: bit.ly/4vXCQw5
In a recent Talking Biotech episode, $CLDI's CEO & Director Eric Poma, Ph.D. discusses Calidi’s systemic #oncolyticvirus platform and CLD-401, designed to avoid immune clearance and selectively replicate in tumor cells.
Listen on @ApplePodcasts: apple.co/3Vfxhg4
In a interview with @RedChip Eric Poma, Ph.D. discusses $CLDI's #RedTail platform & CLD-401, designed to target and lyse tumor cells while delivering an IL-15 superagonist to help activate an anti-cancer immune response.
Watch the clip & full interview: bit.ly/3T59XQ
$CLDI shared preclinical #RedTail data at @myESMO's #ESMO26. A single dose of CLD-401 achieved complete tumor eradication in 80% of mice, while the in situ TCE platform generated ~10 ng/mL of EpCAM-targeted TCE directly in tumors after IV delivery.
🔗 bit.ly/4dXjKQS
Advancing a new generation of cancer therapies at $CLDI. Targeted delivery. Immune activation. Real impact. The future of cancer care is bigger than one approach.
Learn more about our science: bit.ly/4d89lR5
#Oncology
$CLDI will present new preclinical data from its RedTail platform at @myESMO's conference in Madrid.
On October 24, Calidi will share new CLD-401 data and advances from its in situ T-cell engager platform, including CLD-501 and CLD-502.
🔗: bit.ly/4z2PJHQ
#ESMO26
In a new Q&A with @ClinicalLeader1, $CLD's CEO Eric Poma, Ph.D. discusses the science behind CLD-401 and the strategy behind its planned Phase 1 study.
Read more: bit.ly/3U8cLO5
#OncolyticViruses #Oncology #Biotech
$CLDI's CEO Eric Poma, Ph.D. joined @kevinfolta to discuss the potential of #oncolyticviruses for solid tumors and Calidi’s vaccinia-based approach designed to reach tumors and stimulate an immune response.
Listen on @ApplePodcasts: apple.co/3Vfxhg4
#Oncology,
Reaching metastatic tumors remains a major challenge for oncolytic virotherapy.
$CLDI's CEO Eric Poma, Ph.D. discusses why systemic delivery matters and how newer approaches may help therapies reach #tumors more effectively with @LifeScienceDN
Read more: bit.ly/4xTDk7E
$CLDI’s CLD-401 is designed to home to metastatic tumor sites, induce tumor cell lysis and immune priming, and support local production of an IL-15 superagonist to help generate an anti-tumor immune response.
Learn more about our science: bit.ly/4d89lR5
This #WorldCancerResearchDay, $CLDI honors the researchers, clinicians and innovators advancing new approaches for patients with cancer.
Continued research is essential to creating new possibilities and improving the future of cancer care.
#CancerResearch
Earlier this month, $CLDI's CEO Eric Poma, Ph. shared his perspective with Drug Discovery Online on the future of cancer drug discovery and targeted immune activation.
Read more: bit.ly/4iFtPVt
In this #NanoCapPodcast clip, $CLDI's CEO Eric Poma discusses progress toward an #IND application and plans to begin clinical studies following the regulatory process.
Watch the clip and listen to the full episode here: bit.ly/4gumW83
What is an IL-15 superagonist, and how does it connect to $CLDI’s lead program, CLD-401?
CLD-401 is designed to produce IL-15 superagonist at the tumor, helping activate immune cells and support an anti-tumor immune response.
Meet Antonio F. Santidrian, PharmD, Ph.D., CSO and Head of Technical Operations at $CLDI.
Since joining Calidi in 2015, Antonio has led R&D and is a coinventor of the RedTail Platform, bringing 20+ years of anti-cancer translational research experience.
$CLDI’s CEO, Eric Poma, Ph.D., will hold one-on-one meetings with investors at @HCWCO's 28th Annual Global Investment Conference. A virtual presentation will be available on-demand for registered attendees via the conference platform starting 9/11/26.
🔗 bit.ly/3SOk1hC
What’s next for Cancer Drug Discovery?
In a new #DrugDiscovery Online article, $CLDI's CEO Eric Poma, Ph.D. discusses targeted immune activation, drug delivery and Calidi’s approach with CLD-401.
Read more: bit.ly/4iFtPVt
#ICYMI: In a recent @Xtalks feature, $CLDI's CEO Eric Poma, Ph.D., discussed the future of systemically delivered oncolytic virotherapy and Calidi's approach to targeted delivery for #metastaticcancer.
Read more: bit.ly/4eMnGo4
Today we're spotlighting $CLDI's Board of Directors, whose expertise spans biotechnology, clinical development, and corporate leadership.
Learn more: bit.ly/4g36fAJ
#BoardOfDirectors
August is #WorldCancerSupportMonth.
$CLDI recognizes the strength of patients, caregivers, healthcare professionals, and advocates while continuing to advance innovative targeted genetic medicines for the future of #cancercare.